These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 39008204)
1. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Pseudomyxoma Peritonei. Kusamura S; Delhorme JB; Taibi A; Villeneuve L; Deraco M; Dico RL; Glehen O; Moran B Ann Surg Oncol; 2024 Sep; 31(9):6262-6273. PubMed ID: 39008204 [TBL] [Abstract][Full Text] [Related]
2. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer. Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803 [TBL] [Abstract][Full Text] [Related]
3. 2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma. Kepenekian V; Sgarbura O; Marchal F; Villeneuve L; Kusamura S; Deraco M Ann Surg Oncol; 2023 Nov; 30(12):7803-7813. PubMed ID: 37481492 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study. Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159 [TBL] [Abstract][Full Text] [Related]
5. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M; JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455 [TBL] [Abstract][Full Text] [Related]
6. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925 [TBL] [Abstract][Full Text] [Related]
7. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer. Bhatt A; Glehen O; Zivanovic O; Brennan D; Nadeau C; Van Driel W; Bakrin N Ann Surg Oncol; 2023 Dec; 30(13):8115-8137. PubMed ID: 37561343 [TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei. Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
10. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: HIPEC Technologies. Van der Speeten K; Kusamura S; Villeneuve L; Piso P; Verwaal VJ; González-Moreno S; Glehen O Ann Surg Oncol; 2024 Oct; 31(10):7090-7110. PubMed ID: 39037523 [TBL] [Abstract][Full Text] [Related]
11. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341 [TBL] [Abstract][Full Text] [Related]
12. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054 [TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience. Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227 [TBL] [Abstract][Full Text] [Related]
14. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Lurvink RJ; Villeneuve L; Govaerts K; de Hingh IHJT; Moran BJ; Deraco M; Van der Speeten K; Glehen O; Kepenekian V; Kusamura S; Eur J Surg Oncol; 2021 Jan; 47(1):4-10. PubMed ID: 30954350 [TBL] [Abstract][Full Text] [Related]
15. A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario? Rana AKS; Agarwal N; Dutta S; Dokania MK; Goyal H J Gastrointest Cancer; 2019 Dec; 50(4):983-990. PubMed ID: 30140971 [No Abstract] [Full Text] [Related]
16. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742 [TBL] [Abstract][Full Text] [Related]
17. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692 [TBL] [Abstract][Full Text] [Related]
18. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Vaira M; Robella M; Mellano A; Sottile A; De Simone M Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988 [TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766 [TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. Tabrizian P; Shrager B; Jibara G; Yang MJ; Romanoff A; Hiotis S; Sarpel U; Labow DM J Gastrointest Surg; 2014 May; 18(5):1024-31. PubMed ID: 24577736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]